Pancreaticoduodenectomy (Whipple Procedure) + Adjuvant Chemotherapy
Treatment for Pancreatic Cancer
Typical Dosage: Surgical procedure; Adjuvant chemo (e.g., mFOLFIRINOX or Gemcitabine regimen)
Effectiveness
90%
Safety Score
20%
Clinical Trials
12
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
Surgical procedure; Adjuvant chemo (e.g., mFOLFIRINOX or Gemcitabine regimen)
Time to Effect
Immediate tumor removal; long-term survival over years
Treatment Duration
Surgery (1-3 months recovery) + 6 months adjuvant chemotherapy
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75,000
Monitoring:$10,000
Side Effect Mgmt:$20,000
Total Annual:$205,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Remission
$683,333
Comparison vs Palliative Care / No Treatment
Cost Difference
+$150,000/year
More expensive
QALY Difference
+2.50 QALYs
Better outcomes
Dominance
No dominance
Pancreaticoduodenectomy (Whipple Procedure) + Adjuvant Chemotherapy Outcomes
for Pancreatic Cancer
Efficacy Outcomes
Overall Effectiveness
+90%
Remission Rate
+30%
Common Side Effects
Pancreatic fistula
+15%
Delayed gastric emptying
+20%
Bleeding
+7%
Infection
+12%
Surgical mortality
+3%
Neutropenia (from adjuvant chemo)
+25%
Fatigue (from adjuvant chemo)
+10%
Sources:
Active Clinical Trials
4 active trials recruiting for Pancreaticoduodenectomy (Whipple Procedure) + Adjuvant Chemotherapy in Pancreatic Cancer
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
NCT07081360RECRUITINGPHASE3
262 participants
INTERVENTIONAL
Minya, Egypt
Started: Jul 20, 2025
Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.
NCT07148830RECRUITINGNA
100 participants
INTERVENTIONAL
Minya, Egypt
Started: Apr 1, 2024
Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer
NCT07232810RECRUITINGNA
90 participants
INTERVENTIONAL
Minya, Egypt
Started: Dec 1, 2025
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
NCT05116072RECRUITINGPHASE1, PHASE2
36 participants
INTERVENTIONAL
Lille, France
Started: Feb 20, 2022
Completed Clinical Trials
5 completed trials for Pancreaticoduodenectomy (Whipple Procedure) + Adjuvant Chemotherapy in Pancreatic Cancer
Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
NCT00064207COMPLETEDPHASE2, PHASE3
97 participants
INTERVENTIONAL
Brussels, Belgium +58 more
Started: May 1, 2003
Perioperative Therapy for Resectable Pancreatic Cancer
NCT00609336COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Seattle, United States
Started: Jan 1, 2008
Chemotherapy and Radiation Following Pancreatic Surgery
NCT00660270COMPLETEDPHASE2
53 participants
INTERVENTIONAL
St Louis, United States
Started: May 1, 2002
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
NCT00727441COMPLETEDPHASE2
87 participants
INTERVENTIONAL
Baltimore, United States
Started: Jul 2, 2008
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
NCT03153410COMPLETEDEARLY_PHASE1
11 participants
INTERVENTIONAL
Baltimore, United States
Started: Sep 27, 2018